Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives.

Autor:	Gilardi L; Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS., Airò Farulla LS; Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Bonatto E; Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS., Ceci F; Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Jazyk:	angličtina
Zdroj:	Current opinion in oncology [Curr Opin Oncol] 2024 Nov 01; Vol. 36 (6), pp. 514-520. Date of Electronic Publication: 2024 Jun 12.
DOI:	10.1097/CCO.0000000000001057
Abstrakt:	Purpose of Review: There is a critical need for timely and accurate decisions in breast cancer management. This narrative review aims to clarify the potential role of novel PET tracers in optimizing treatment strategies for different breast cancer subtypes. Recent Findings: 2-deoxy-2-[18F]-fluoro-D-glucose PET/computed tomography (FDG PET/CT) has a pivotal role in response assessment in metastatic breast cancer, despite its limitations in certain histological and molecular subtypes. Further PET radiopharmaceuticals have been proposed to address these clinical needing. Summary: FES PET/CT demonstrates its usefulness in assessing ER expression and predicting response to therapy in luminal breast cancer, with implications for treatment optimization and monitoring. In HER2-positive and HER2-low breast cancer, HER2-targeted PET tracers show potential in assessing HER2 status, while their accuracy in predicting response to targeted therapies is still debated. PARP-targeted PET imaging holds potential for selecting patients for PARP inhibitors treatments, particularly in triple-negative breast cancer (TNBC), where imaging tools are crucial due to the absence of specific targets. Immunotherapy and antibody-drug conjugates (ADCs) are emerging treatment options for TNBC, and PET imaging targeting immune checkpoints could aid in treatment selection and response monitoring. The dynamic role of PET/CT imaging in tailoring breast cancer treatments requires further multidisciplinary research to validate the clinical utility of targeted tracers. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu